Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nautilus BiotechnologyNAUT +0.22%28 Days Payable is 6,938.04 as of Jun. 2026. GuruFocus rates NAUT with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 703 Biotechnology companies, Nautilus Biotechnology ranks better than 96.73% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NAUT vs SLNCF, CHRS, AVXL: Days Payable Comparison
For the Biotechnology subindustry, Nautilus Biotechnology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nautilus Biotechnology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's Days Payable distribution charts can be found below:
* The bar in red indicates where Nautilus Biotechnology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nautilus Biotechnology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nautilus Biotechnology (NAUT) has a Days Payable of 6,938.04 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nautilus Biotechnology and its competitors. According to the industry distribution chart, Nautilus Biotechnology ranks #23 out of 703 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Nautilus Biotechnology's Days Payable too high?
Nautilus Biotechnology's current Days Payable is 6,938.04. The Biotechnology industry median Days Payable is 112.39. Nautilus Biotechnology's value of 6,938.04 is 6073.2% above this industry median. Based on the distribution chart, Nautilus Biotechnology ranks #23 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Nautilus Biotechnology has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Nautilus Biotechnology's Days Payable compare to SLNCF and CHRS?
According to the Biotechnology industry distribution chart, Nautilus Biotechnology ranks #23 out of 703 companies for Days Payable. This places Nautilus Biotechnology in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.39. Nautilus Biotechnology's value of 6,938.04 is 6073.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.39, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nautilus Biotechnology's current Days Payable of 6,938.04 is 6073.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nautilus Biotechnology and its competitors. For the Biotechnology industry, the median Days Payable is 112.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nautilus Biotechnology's current Days Payable is 6,938.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nautilus Biotechnology stock overvalued right now?
Nautilus Biotechnology (NAUT) has a current Days Payable of 6,938.04. The current Days Payable is 6,938.04 and 6073.2% above the Biotechnology industry median of 112.39. Nautilus Biotechnology's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nautilus Biotechnology (NAUT), the current Days Payable is 6,938.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
28GF Score
Get the complete analysis for NAUT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NAUT has been successfully added to your 
